Active ingredients: lorlatinib
What it is used for
LORVIQUA has provisional approval in Australia for the treatment of patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor; or alectinib as the first ALK inhibitor therapy; or ceritinib as the first ALK inhibitor therapy. The decision to approve this indication has been made on the basis of tumour response rate and duration of response in a single arm study. Continued approval of this indication depends on verification and description of benefit in a confirmatory trial.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Protect from Light
- Protect from Moisture
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Oval (8.5 x 17 mm) lavender film coated tablet, debossed with 'Pfizer' on one side and 'LLN 100' on the other side.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November 1, 2021. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient lorlatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.